Yahoo Poland Wyszukiwanie w Internecie

Search results

  1. 31 mar 2020 · In this study, we found that ivermectin, an effective antiparasitic drug that has been approved for patients to orally treat onchocerciasis for over 30 years, displayed potent antitumour activity against ESCC cells in vitro and in nude mice.

  2. 7 gru 2021 · Esophageal squamous cell carcinoma (ESCC) is one of the most common and fatal malignancies in China [1, 2], which is considered as an aggressive cancer due to its poor prognosis and high mortality rate with a 5-year survival rate of only about 20% [3–5].

  3. 8 maj 2024 · The treatment for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) with immune checkpoint inhibitors (anti-PD1) with or without chemotherapy has led to an improvement in survival.

  4. 29 maj 2024 · Immune checkpoint inhibitors (ICIs) have demonstrated superior clinical efficacy in prolonging overall survival (OS) as the second-line treatment for advanced or metastatic esophageal squamous cell carcinoma (ESCC), and were recommended by the guidelines.

  5. In this study, we found that ivermectin, an effective antiparasitic drug that has been ap-proved for patients to orally treat onchocerciasis for over 30 years, displayed potent antitumour activity against ESCC cells in vitro and in nude mice.

  6. 7 gru 2021 · Results: Our results determined that ivermectin significantly inhibited the proliferation of ESCC cells in vitro and in vivo. Furthermore, we found that ivermectin markedly mediated mitochondrial dysfunction and induced apoptosis of ESCC cells, which indicated the anti-proliferative effect of ivermectin on ESCC cells was implicated in ...

  7. 23 wrz 2023 · Ivermectin not only effectively inhibited the growth, migration and aggression of esophageal squamous cancer cells, but also enhanced chemosensitivity to cisplatin and 5-fluorouracil . Taken together, ivermectin has shown marked antitumor effects alone or in combination with chemotherapeutics.

  1. Ludzie szukają również